BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

Sep 28, 2018

|

NEW YORK (GenomeWeb) – The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor's susceptibility to PARP inhibitor treatment, a new study has found.

PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with defective DNA repair. But not all patients respond as expected.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

To read the full story....

Breaking News

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Featured White Papers

What's Popular?

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Full BRCA1 Gene Deletion Suspected to Contribute to Patient's Long PARP Inhibitor Response

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Sponsorships